Latest News

TSMC is the world's largest semiconductor foundry, which gives it immense pricing power.

Can Intel's plants win back what AMD took one server chip at a time?

With the crypto majors set to grow, ETFs are a great way to get exposure.

Two different tools for two different jobs.

Cimpress (NASDAQ:CMPR) used its 2026 Investor Day to outline a strategy centered on higher-value customers, expanded offerings in “elevated products,” manufacturing and supply-chain efficiency, shared technology platforms and artificial intelligence. Founder, Chairman and CEO Robert Keane said the

This ETF's impressive track record has built immense for long-term investors.

There's more than just a cost-of-living adjustment in store for Social Security recipients.

The software giant split its shares nine times over its first 17 years as a public company. Is a 10th split on the way?

These stocks should hold up well no matter what the future holds for the overall market.

Soaring long-duration Treasury bond yields are sending an unmistakable message to President Trump, Wall Street, and investors.

The chip stock has more than tripled this year. Can it actually do it again?

Rogers (NYSE:ROG) outlined a plan to grow annual sales to more than $1.5 billion by 2030, supported by expansion in its core markets and targeted opportunities in AI data centers, battery systems and electromagnetic interference, or EMI, shielding. At the company’s 2026 Analyst and Investor Day, Pr

This Canadian dividend stock has a great combination of a 5.8% dividend yield, resilient cash flow, and billions of dollars in growth projects makes it a compelling long-term income stock.

CrowdStrike and Palo Alto are positioned for long-term growth.

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end. PBH is a chroni